NTRK2 and cancer: The TrkB inhibition via pharmacological or siRNA against TrkB causes loss of transcription factors linked to epithelial to mesenchymal transition (EMT), suggesting that TrkB is involved in the full acquisition of EMT in cancer cells [60].